How to Reconstitute GHK-Cu: Syringe Selection, Needle Gauge, and Dosing

What Is GHK-Cu and Why Do Women Use It?

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide first isolated from human plasma in 1973 by Loren Pickart. Your body produces it, and plasma concentrations decline significantly with age: levels measured at roughly 200 ng/mL in young adults drop to approximately 80 ng/mL by age 60 according to Pickart's foundational work catalogued on.

Women seek GHK-Cu for several reasons that map closely to life-stage biology:

• Skin collagen and elasticity. Estrogen supports collagen synthesis, so the approximately 30% drop in skin collagen that occurs in the first five years after menopause creates a window where copper peptide signaling may matter most.
• Hair follicle support. GHK-Cu has been shown in cell studies to stimulate follicle size and increase expression of vascular endothelial growth factor (VEGF), relevant to female pattern hair loss, which affects roughly 40% of women by age 50.
• Wound healing. Postoperative or post-procedure skin repair is a documented application in the surgical literature.
• PCOS and androgenic alopecia. Women with PCOS experience androgenic hair thinning; GHK-Cu is used off-label as an adjunct to conventional treatments such as spironolactone or minoxidil.

GHK-Cu is not FDA-approved as a drug. In the United States it is sold as a research compound or, in topical form, as a cosmetic ingredient. The injectable form requires reconstitution from lyophilized powder. That process is what this guide covers, step by step.

Understanding Bacteriostatic Water: The Only Diluent You Should Use

Why bacteriostatic water, not sterile water

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as a preservative. That single additive gives your reconstituted vial a shelf life of up to 28 days under refrigeration, compared to sterile water for injection (SWFI), which should be used within 24 hours once a vial is punctured per USP General Chapter 797 sterility standards.

For a peptide you plan to dose daily or several times per week, BWFI is the correct choice.

Where to source bacteriostatic water

Purchase BWFI from a licensed U.S. Compounding pharmacy or a medical supply retailer. Common presentations are 10 mL and 30 mL multi-dose vials. Check the label: it must read "bacteriostatic water for injection, USP" and list benzyl alcohol as the preservative. Saline, normal saline, and distilled water are not appropriate substitutes for injectable GHK-Cu.

Benzyl alcohol and life-stage considerations

Benzyl alcohol is a known neonatal toxicant. The FDA warns explicitly against its use in neonates and recommends avoiding BWFI in pregnant and lactating women. This is covered in detail in the pregnancy section below.

Calculating Your Reconstitution Volume: The GHK-Cu Dosing Calculator

Standard concentration formula

The most common working concentration for subcutaneous GHK-Cu is 1 mg per 1 mL. At that concentration, a 50 mg vial reconstituted with 50 mL of BWFI gives you 50 individual 1 mg doses. That is more diluent than most 50 mg vials can practically hold, so most practitioners work at a higher concentration:

| Vial size | BWFI added | Working concentration | Volume per 0.5 mg dose | |-----------|------------|----------------------|------------------------| | 5 mg | 2.5 mL | 2 mg/mL | 0.25 mL (25 units on U-100) | | 5 mg | 5 mL | 1 mg/mL | 0.5 mL (50 units on U-100) | | 10 mg | 5 mL | 2 mg/mL | 0.25 mL (25 units on U-100) | | 10 mg | 10 mL | 1 mg/mL | 0.5 mL (50 units on U-100) |

"Units" here refers to the graduation marks on a U-100 insulin syringe, where 100 units equals 1 mL. Using insulin-syringe unit markings is the most practical way to draw small, accurate volumes.

Dose ranges cited in research

Human dosing data for injectable GHK-Cu is sparse. Most protocols in the compounding and research community use 0.5 mg to 2 mg per injection, administered subcutaneously near the target tissue (scalp, face, abdomen). A 2015 review of GHK biological activity notes that physiological GHK concentrations in tissue are in the nanomolar to low micromolar range, which contextualizes why even sub-milligram doses may produce biological effects.

WomanRx life-stage dosing framework (based on practitioner consensus, not RCT data):

| Life stage | Common starting dose | Frequency | Notes | |------------|---------------------|-----------|-------| | Reproductive years (18-40) | 0.5 mg SC | 3x/week | Cycle phase may affect skin hydration baseline | | Perimenopause (40-55) | 0.5-1 mg SC | Daily or 5x/week | Collagen loss accelerates; some practitioners dose more frequently | | Post-menopause (>55) | 1 mg SC | Daily | Use alongside topical retinoids or HRT if appropriate | | Pregnancy / Lactation | Avoid | N/A | No safety data; benzyl alcohol contraindicated |

This framework is based on clinical practitioner consensus, not randomized controlled trial evidence in women. The evidence gap is real, and you deserve to know it.

Syringe Selection: Choosing the Right Tool

The insulin syringe is the standard

For subcutaneous GHK-Cu injection, a U-100 insulin syringe is the correct format. These syringes hold 1 mL maximum, are pre-attached to a fine needle, and their unit-based graduations make dose calculation straightforward when you are working in the 0.25 mL to 0.5 mL range.

Three barrel sizes are commercially available:

• 0.3 mL (30-unit): Best for doses below 0.3 mg at 1 mg/mL; limits dead space.
• 0.5 mL (50-unit): The most practical all-purpose option for GHK-Cu; covers 0.25 mL to 0.5 mL doses cleanly.
• 1.0 mL (100-unit): Useful if your concentration is low (1 mg/mL) and your dose is 0.5 mg or higher.

Needle gauge: 29 G, 30 G, or 31 G

Gauge refers to the needle's outer diameter. Higher numbers mean thinner needles.

| Gauge | Outer diameter | Pain level | Best use for GHK-Cu | |-------|---------------|------------|---------------------| | 27 G | 0.41 mm | Moderate | Acceptable but not preferred | | 29 G | 0.34 mm | Low | Standard subcutaneous SC choice | | 30 G | 0.31 mm | Very low | Preferred for facial SC injection | | 31 G | 0.26 mm | Minimal | Best for periorbital or scalp micro-injection |

For most women doing abdominal or thigh SC injections, a 29 G, 0.5-inch needle provides a practical balance of flow rate and comfort. GHK-Cu in BWFI is a thin, low-viscosity solution, so there is no meaningful risk of the peptide shearing through a 31 G bore.

Needle length: 0.5 inch vs. 1 inch

Subcutaneous tissue sits below the dermis and above muscle. In the abdomen:

• Women with a BMI <25 typically have 8-12 mm of subcutaneous fat at the periumbilical site.
• Women with a BMI of 25-35 have 12-25 mm or more.

A 0.5-inch (12.7 mm) needle inserted at a 45-degree angle reaches subcutaneous tissue reliably in most women without intramuscular penetration per injection technique guidance published by the American Diabetes Association. For scalp micro-injection, a 4 mm or 6 mm needle is preferable to minimize the risk of periosteal contact.

Step-by-Step Reconstitution Protocol

What you need

• Lyophilized GHK-Cu vial
• Bacteriostatic water for injection, USP (multi-dose vial)
• Two alcohol swabs (70% isopropyl)
• One 1 mL insulin syringe (29 G to 31 G, 0.5-inch)
• Sharps container

The process

1. Wash your hands with soap and water for at least 20 seconds.
2. Swab both vial tops with separate 70% isopropyl alcohol swabs. Allow to air-dry for 15-30 seconds. Do not blow on them.
3. Draw the BWFI. Insert the insulin syringe needle through the center of the BWFI vial septum at a slight angle. Draw back the plunger to pull in your calculated volume. For a 5 mg vial at 2 mg/mL, you need 2.5 mL total; you will need to draw this in multiple passes with a 1 mL syringe.
4. Inject slowly. Push the BWFI into the GHK-Cu vial by directing the stream down the inner wall of the vial, not directly onto the powder cake. Forcing liquid through the lyophilized powder at high velocity can degrade the peptide structure.
5. Do not vortex. Gently swirl the vial in a circular motion until the powder fully dissolves. The solution should be clear to pale blue-green depending on copper loading. Cloudiness or particulate matter means discard.
6. Label the vial with the date of reconstitution, concentration, and your initials.
7. Refrigerate immediately at 2-8°C (36-46°F). Do not freeze reconstituted GHK-Cu; peptide stability data shows freeze-thaw cycles degrade copper-peptide complexes.
8. Discard at 28 days regardless of remaining volume.

Drawing a dose for injection

1. Swab the reconstituted GHK-Cu vial top. Allow to dry.
2. Attach a fresh needle if your syringe is of the detachable type (most insulin syringes are fixed-needle; use a new syringe each time).
3. Insert the needle, invert the vial, and draw back to your target volume mark plus a small air bubble.
4. Expel the air bubble.
5. Swab the injection site (abdomen, thigh, or scalp area).
6. Pinch the skin, insert at 45 degrees for a 0.5-inch needle or 90 degrees for a 4-6 mm needle, inject slowly over 5-10 seconds, withdraw, apply light pressure.

Pregnancy, Lactation, and Contraception: What You Must Know

GHK-Cu is not approved by the FDA in any injectable form. No human trials have evaluated its safety in pregnancy or lactation. Avoid injectable GHK-Cu entirely if you are pregnant, trying to conceive, or breastfeeding.

Here is what the current data field looks like:

Pregnancy

There is no pregnancy category assigned to GHK-Cu because it has not gone through the FDA drug approval process. Animal reproductive toxicology data is absent from the peer-reviewed literature. The copper ion component is a micronutrient required in pregnancy at approximately 1 mg per day per NIH dietary reference intakes, but pharmacological concentrations delivered by injection are a different matter entirely. Given the absence of data, the precautionary principle applies: do not use injectable GHK-Cu during pregnancy.

Lactation

Benzyl alcohol, the preservative in bacteriostatic water, transfers into breast milk and at sufficient concentrations can cause metabolic acidosis in neonates ("gasping syndrome"). Even if the GHK-Cu peptide itself were safe during breastfeeding, the diluent is not. Topical GHK-Cu serums that do not contain benzyl alcohol present a different and potentially lower risk profile, but systemic absorption through intact skin is minimal and not clinically characterized. Discuss topical use with your provider.

Trying to conceive

If you are actively trying to conceive, pause injectable GHK-Cu in the luteal phase of each cycle when implantation may be occurring. Because copper affects prostaglandin synthesis and uterine environment, any uncertainty about pharmacological copper delivery during potential early pregnancy warrants caution.

Contraception

No specific contraception requirement exists for GHK-Cu the way it does for known teratogens such as isotretinoin or methotrexate. A meaningful pregnancy risk cannot be formally quantified because human data is absent. Women of reproductive age using injectable GHK-Cu should use reliable contraception as a precaution, and should stop the peptide immediately if a positive pregnancy test is obtained.

Who This Protocol Is Right For, and Who Should Pause

Potentially appropriate candidates

• Post-menopausal women seeking adjunct support for skin collagen loss or female pattern hair thinning, who are working with a provider experienced in peptide therapeutics.
• Perimenopausal women with documented androgenic alopecia or accelerated photoaging who have tried first-line options (topical minoxidil, low-level laser therapy, retinoids) and want to add a peptide protocol.
• Women in reproductive years using GHK-Cu for localized wound healing or hair loss, who are using reliable contraception and are not pregnant or breastfeeding.

Situations requiring pause or avoidance

• Pregnancy or suspected pregnancy. Stop immediately.
• Breastfeeding. Avoid injectable form.
• Known copper sensitivity or Wilson's disease. GHK-Cu delivers copper directly; Wilson's disease is characterized by impaired copper excretion, and additional copper loading is contraindicated.
• Allergy to benzyl alcohol.
• Active skin infection at intended injection site.

Injection Site Considerations by Life Stage and Condition

Scalp injection for hair loss

Women with PCOS-related androgenic alopecia or post-menopausal female pattern hair thinning most commonly target the frontal hairline and vertex. Use a 31 G, 4 mm needle. Inject into the superficial subcutaneous layer, not intradermally. Space injections 1-2 cm apart across the affected zone. Scalp injections sting more than abdominal SC; applying a topical anesthetic cream (lidocaine 4%) 30-45 minutes prior reduces discomfort.

Facial injection for collagen support

The periorbital and cheek subdermal space requires precision. A 31 G, 4 mm or 6 mm needle at a concentration of 2 mg/mL allows a very small volume (0.05-0.1 mL per injection point). This technique is closer to mesotherapy than to standard SC injection and should be performed by a licensed practitioner if you are new to facial injections.

Abdominal SC for systemic delivery

If your goal is systemic GHK-Cu exposure (for example, as part of a broader anti-aging protocol), the abdomen 2 inches from the navel is the most forgiving site. Rotate sites each injection. A 29 G, 0.5-inch needle at 45 degrees is the correct approach. Avoid injecting into the same spot more than twice per week to prevent localized lipodystrophy.

Storage, Stability, and Quality Signals

Reconstituted GHK-Cu is stable at 2-8°C for up to 28 days when prepared with BWFI. Research on copper-peptide complex stability indicates that the Cu(II) coordination bond is vulnerable to oxidative stress and freeze-thaw cycling.

Signs that your vial should be discarded:

• Cloudy or precipitated solution
• Color change beyond pale blue-green to brown or amber
• Visible particulate matter
• Vial has been unrefrigerated for more than 4 hours
• More than 28 days since reconstitution

Because GHK-Cu is not FDA-regulated as a drug, there is no mandatory certificate of analysis (COA) requirement for research-grade vials. Choose suppliers who provide third-party HPLC purity testing with each lot. A minimum acceptable purity is 98% by HPLC per general USP peptide purity standards.

The Evidence Gap: What We Know and What We Don't

Women have been historically underrepresented in peptide research. The published human data on GHK-Cu is largely limited to small topical studies, in vitro work, and animal models. The scalp injection and subcutaneous injection protocols used in clinical practice are extrapolated from:

1. Cell culture data showing GHK stimulates collagen and VEGF gene expression (Pickart et al., 2015).
2. Topical RCT data in photoaging (Leyden et al., 2018, Cosmetic Dermatology) showing statistically significant improvement in fine lines vs placebo.
3. Animal wound-healing studies showing accelerated re-epithelialization at doses approximating 0.5-2 mg/kg.

No randomized controlled trial has tested injectable GHK-Cu in women for hair loss, skin aging, or any other endpoint. The protocols in this article represent current practitioner consensus and physiological extrapolation, not level-I evidence. Your provider should disclose this clearly before any injectable peptide protocol.